XNAS · Healthcare · Biotechnology
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | -0.76 | -1.11 | -46.05% | $0 | ❌ Miss | -4.77% | -25.00% | — |
| 2026-03-12 | Q4 2025 | -1.15 | -0.99 | +13.91% | $0 | ✅ Beat | -1.72% | +24.43% | +22.16% |
| 2025-11-06 |
| Q3 2025 |
| -1.20 |
| -1.09 |
| +9.17% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -1.24 | -1.14 | +8.06% | $0 | ✅ Beat | +0.99% | +37.00% | +22.00% |
| 2025-03-10 | Q4 2024 | -0.74 | -1.37 | -85.14% | $0 | ❌ Miss | -0.20% | -2.82% | -36.49% |
| 2024-11-07 | Q3 2024 | — | -1.10 | — | $0 | — | +2.27% | -1.69% | -12.74% |
Showing last 6 quarters.